Real world health data (RWD) is health information generated during routine care and everyday life rather than exclusively through controlled clinical trials. It includes electronic health records, claims, pharmacy transactions, registries, diagnostic reports, wearable-device readings and patient-reported outcomes. When collected, standardised and analysed responsibly, RWD can reveal how diseases, treatments and healthcare systems perform in diverse populations.
For healthcare organisations, pharmaceutical companies, researchers and AI startups, the value of RWD lies in its scale and context. It can help answer questions about treatment effectiveness, safety, adherence, health access and outcomes across real patients—including groups that are often under-represented in trials. However, more data does not automatically create better evidence. Strong governance, interoperability, statistical design and clinical validation are essential.
What Is Real World Health Data?
Real world health data is data relating to patient health or healthcare delivery that is collected outside a traditional randomised controlled trial. It may be structured, such as diagnosis codes and laboratory values, or unstructured, such as clinical notes and medical images.
Common examples include:
- Electronic health records (EHRs): Diagnoses, medications, allergies, procedures, laboratory results and clinical notes.
- Insurance and claims data: Billing events, hospitalisations, procedures, reimbursement and utilisation patterns.
- Pharmacy data: Prescriptions, dispensing records, refills and medication persistence.
- Patient registries: Longitudinal information about people with a specific disease, treatment or clinical characteristic.
- Medical devices and wearables: Heart rate, glucose, oxygen saturation, activity, sleep and other physiological measurements.
- Patient-generated data: Surveys, symptom diaries, patient-reported outcomes and home-monitoring records.
- Public health datasets: Disease surveillance, immunisation, mortality and health programme data.
- Genomic and imaging data: Sequencing, pathology, radiology and other diagnostic information linked to clinical outcomes.
RWD is broader than trial data because it captures routine practice. It may reflect multiple hospitals, clinicians, socioeconomic groups, adherence levels and coexisting conditions. That realism is valuable, but it also introduces missingness, inconsistent coding, selection bias and potential confounding.
Real World Data vs Real World Evidence
The terms RWD and real world evidence (RWE) are related but not interchangeable.
- Real world data is the raw or processed information collected from routine healthcare and daily life.
- Real world evidence is the clinical or operational insight generated by analysing RWD using a defined research question and suitable methodology.
For example, records showing prescriptions and hospital visits are RWD. A carefully designed study using those records to estimate whether a medicine reduces hospitalisation risk produces RWE.
The distinction matters because evidence quality depends on more than the dataset itself. Researchers must define the population, exposure, comparator, outcomes, follow-up period and analytical method. A large database can still produce misleading conclusions if treatment groups differ systematically or if outcomes are measured inconsistently.
Why Real World Health Data Matters
1. It reflects routine clinical practice
Clinical trials typically use strict eligibility criteria, controlled protocols and close monitoring. RWD captures what happens after products and services reach normal healthcare settings. This includes older adults, people with multiple conditions, patients with irregular adherence and populations with different access to care.
2. It supports faster research
Existing clinical and administrative datasets can reduce the time needed to identify eligible patients, measure outcomes and monitor safety. RWD does not replace prospective studies, but it can support feasibility analysis, external controls, post-market surveillance and pragmatic research.
3. It enables longitudinal analysis
Linked records can show a patient’s journey over months or years: diagnosis, referral, treatment, response, complications, recurrence and follow-up. Longitudinal data is especially useful for chronic diseases such as diabetes, cardiovascular disease, cancer and chronic kidney disease.
4. It reveals healthcare gaps
RWD can expose differences in diagnosis, treatment initiation, geographic access, referral delays and outcomes. In India, analysis across public and private systems may help identify uneven access to specialists, diagnostics and essential medicines—provided datasets are representative and responsibly linked.
5. It improves healthcare AI
Machine-learning systems need data that resembles the environment in which they will operate. Real-world health data can support risk prediction, clinical decision support, patient segmentation, resource planning and remote monitoring. Yet AI models must be evaluated for calibration, fairness, drift and clinical usefulness—not just accuracy on a retrospective dataset.
Major Applications of Real World Health Data
Drug development and pharmacovigilance
Pharmaceutical and biotechnology companies use RWD to understand treatment pathways, identify unmet needs, design pragmatic studies and monitor post-market safety. Claims and EHR data can help detect unusual adverse-event patterns, while patient registries may provide disease-specific outcome information.
RWD can also support external comparator arms in selected research settings. This requires careful alignment of eligibility criteria, baseline characteristics, index dates and outcome definitions. Poorly constructed comparators can create substantial bias.
Population health management
Health systems can use RWD to identify high-risk patients, estimate care demand and target preventive interventions. For example, a programme may combine recent admissions, laboratory trends and medication history to identify patients who need follow-up for uncontrolled hypertension or diabetes.
Clinical decision support
When integrated into clinical workflows, RWD-derived tools can provide alerts, risk scores and treatment insights. Effective systems should minimise alert fatigue, explain relevant factors and allow clinicians to review the underlying evidence. A model that performs well in a data science environment may fail if it disrupts workflow or relies on unavailable inputs.
Remote and home-based care
Wearables, connected devices and mobile applications can extend monitoring beyond hospitals. Continuous or frequent measurements may reveal deterioration earlier than occasional clinic visits. Device data must still be checked for sensor quality, user adherence, calibration and demographic performance differences.
Health economics and outcomes research
RWD can support analysis of healthcare utilisation, costs, readmissions, treatment persistence and quality-of-life outcomes. These analyses can inform reimbursement, procurement and programme design, but cost data varies considerably by payer, geography and accounting method.
Medical imaging and pathology
Large repositories of radiology and pathology images paired with reports and outcomes can support computer-vision research. Dataset construction should address label quality, scanner variation, institution effects and patient privacy. External validation across hospitals is critical before clinical deployment.
Key Data Sources in India
India’s health data landscape is diverse and fragmented. Potential sources include hospital information systems, diagnostic laboratories, pharmacy networks, insurance claims, disease registries, public health programmes, telemedicine platforms and consumer health applications. The Ayushman Bharat Digital Mission (ABDM) is intended to support interoperable digital health infrastructure through components such as health IDs and registries, subject to applicable policies, consent mechanisms and implementation standards.
For an Indian AI or health-tech project, the practical question is not simply whether data exists. Teams should assess:
- Whether the data represents the intended patient population and care setting.
- Whether consent, purpose limitation and access controls are documented.
- Whether records can be linked reliably without exposing unnecessary identity information.
- Whether clinical terminology, units, timestamps and coding systems are consistent.
- Whether the dataset includes enough outcome events for meaningful evaluation.
- Whether data can legally and operationally be used for model development or research.
India-specific variation is important. A model trained in a metropolitan tertiary hospital may not generalise to district hospitals, smaller clinics or rural settings. Differences in language, documentation practices, device availability, referral patterns and disease prevalence can affect performance.
Data Quality Challenges
Missing and incomplete records
Missingness is rarely random. A test may be absent because a clinician did not order it, a patient could not afford it or a facility lacked the equipment. Treating missing values as harmless can introduce bias.
Inconsistent coding
The same condition may be recorded using different terms, codes or abbreviations. Medication names may vary by brand and generic name. Clinical NLP pipelines must handle spelling variation, multilingual text, negation and context.
Measurement and label errors
Diagnosis codes are often proxies rather than confirmed clinical truth. A billing code may indicate a suspected condition, historical disease or administrative necessity. Outcome definitions should be validated against charts, laboratory data or multiple corroborating signals where possible.
Data silos and interoperability
Healthcare data may be distributed across providers that use different systems and identifiers. Interoperability requires common data models, terminology mapping, secure APIs and clear data-sharing agreements. Record linkage should be tested for false matches and missed matches.
Temporal complexity
Healthcare data contains multiple dates: symptom onset, order time, collection time, result time, prescription time and administration time. Incorrect temporal logic can cause data leakage—for example, using information recorded after the prediction point to claim an earlier prediction.
Privacy, Security and Responsible Use
Health information is highly sensitive. Organisations handling RWD should apply privacy-by-design rather than treating compliance as a final checklist. Important controls include data minimisation, role-based access, encryption, audit logging, retention limits, secure computation environments and documented incident response.
In India, teams should evaluate obligations under the Digital Personal Data Protection Act, 2023, along with applicable sectoral requirements, contractual commitments and institutional ethics processes. Depending on the project, additional review may be needed from an ethics committee, institutional review board or data-access committee.
De-identification reduces risk but does not guarantee anonymity, especially when datasets contain longitudinal, genomic, geographic or rare-disease information. Re-identification risk should be assessed before release or linkage. Synthetic data can help with prototyping, but it should not automatically be assumed to preserve clinical validity or eliminate privacy concerns.
Responsible use also includes transparency. Patients and communities should understand, where appropriate, how their information supports research or AI. Organisations should document data provenance, intended use, known limitations and model performance across relevant subgroups.
How to Build a Reliable RWD Pipeline
A robust real world health data programme usually follows these steps:
1. Define the decision or research question. Specify the population, intervention or exposure, comparator, outcome and time horizon.
2. Create a data map. Document source systems, fields, owners, update frequency, identifiers and permitted uses.
3. Standardise terminology. Map diagnoses, medications, procedures, laboratory units and outcomes to consistent vocabularies.
4. Establish quality rules. Measure completeness, validity, uniqueness, consistency, timeliness and plausibility.
5. Design privacy controls. Separate identifiable data from analytical data where possible and restrict access according to role.
6. Build an analysis-ready cohort. Apply explicit inclusion criteria, index dates, washout periods and follow-up rules.
7. Control bias and confounding. Use stratification, propensity scores, matching, weighting, sensitivity analyses or causal methods when appropriate.
8. Validate externally. Test the findings or model on a different hospital, geography, time period or patient group.
9. Monitor after deployment. Track data drift, performance, subgroup gaps, alert burden and clinical outcomes.
Best Practices for AI Using Real World Health Data
AI teams should separate development, tuning and final evaluation datasets at the patient level. Random row-level splits can leak information when multiple visits from the same person appear in both training and test sets.
Recommended practices include:
- Define the prediction time and ensure only information available then is used.
- Report calibration, sensitivity, specificity, positive predictive value and clinically meaningful utility—not only area under the curve.
- Evaluate performance by age, sex, geography, language, facility type and other relevant subgroups.
- Document dataset provenance, exclusions, label construction and preprocessing.
- Use prospective or silent-mode evaluation before changing clinical decisions.
- Establish human oversight, escalation paths and rollback procedures.
- Reassess models when clinical practice, coding, devices or population characteristics change.
The strongest health AI products solve a defined clinical or operational problem and demonstrate measurable benefit. A sophisticated model trained on poorly governed data is not a dependable healthcare solution.
Future of Real World Health Data
The next phase of RWD will involve greater use of interoperable records, multimodal datasets, federated learning, privacy-enhancing technologies and near-real-time analytics. Instead of moving all patient data into one central repository, federated approaches may allow approved algorithms to run across institutions while sensitive records remain locally governed.
Large language models may assist with clinical-note structuring, cohort discovery and evidence summarisation, but they require strict safeguards against hallucination, data leakage and unsupported clinical recommendations. Combining RWD with patient-generated data and environmental information could improve prevention and personalised care, provided consent and representativeness are addressed.
The central principle remains simple: trustworthy health intelligence depends on trustworthy data practices. Better collection, documentation, governance and validation will create more value than scale alone.
FAQ: Real World Health Data
Is real world health data the same as electronic health record data?
No. EHRs are one important source of RWD. RWD also includes claims, registries, pharmacy records, wearables, patient-reported outcomes, imaging, genomic data and public health datasets.
Can real world health data replace clinical trials?
Usually not. Randomised trials remain important for establishing causal efficacy under controlled conditions. RWD complements trials by showing effectiveness, safety, utilisation and outcomes in routine practice.
How is real world health data used in AI?
It can train and evaluate models for risk prediction, diagnosis support, demand forecasting, remote monitoring and population health. Successful deployment requires privacy protection, representative data, external validation and ongoing monitoring.
What is the biggest challenge with RWD?
Data quality and bias are among the biggest challenges. Missing information, inconsistent coding, non-representative populations and confounding can produce unreliable conclusions unless addressed systematically.
How can an Indian startup begin using RWD responsibly?
Start with a clearly defined use case, obtain lawful access and appropriate approvals, minimise identifiable data, document provenance, establish quality checks and validate results across relevant Indian care settings.